10 days
CASTA stroke trial treatment period.
Protocol / Research Dosing Guide
Cerebrolysin Dosage Guide: Clinical Evidence, Routes and Safety
An evidence-organized Cerebrolysin reference separating prescription liquid studied internationally from an unvalidated powder-style research vial.
Last reviewed September 15, 202622 minute readResearch information only
Level 5 — Randomized human trialsMixed clinical findingsNot FDA approved
Cerebrolysin Quick Start
Cerebrolysin is not one defined peptide. The clinical product is a ready-to-use porcine-brain hydrolysate containing peptides and amino acids. It has extensive but mixed international clinical research and is not approved in the United States.
Why researchers care
Stroke, brain injury, and cognitive research
Class
Porcine-brain-derived peptide and amino-acid mixture
Route reported
Slow IV infusion or IM injection in clinical studies
Cycle length
10–21 day courses and four-week studies; indication specific
Regulatory status
Prescription product in some countries; not FDA approved
Loading supplier information
Cerebrolysin Dosing Protocol and Schedule
The supplied source reports a 20-to-32 mg daily community ramp for powder-style research vials. That scale is hundreds of times below clinical liquid studies and is not trial validated or interchangeable with the 215.2 mg/mL prescription liquid.
| Phase or study | Amount | Frequency / evidence |
|---|---|---|
| Week 1 | 20 mg daily | Community research-vial report |
| Week 2 | 24 mg daily | Community research-vial report |
| Week 3 | 28 mg daily | Community research-vial report |
| Week 4+ | 32 mg daily | Community research-vial report |
Clinical studies instead used ready-to-use liquid measured in mL, commonly 5–50 mL daily in indication-specific supervised courses. Do not convert the community ramp into a clinical regimen.
Cerebrolysin Supplies Needed
Neutral research-material planning only. This does not establish an appropriate amount or route.
Research planning item
Exact labeled research vial
Research planning item
Measured diluent volume
Research planning item
U-100 measurement reference
Research planning item
Alcohol swabs
Research planning item
Appropriate sharps container
Research planning item
Written concentration label
Cerebrolysin Reconstitution Calculator
Vial-format concentration math
Concentration
20 mg/mL
Draw volume
1 mL
U-100 units
100
Mathematical draws
3
Arithmetic only. The entered amount is not a recommendation and does not establish suitability.
Best Time to Take Cerebrolysin: Morning or Night?
Time of day
Not established as a universal factor; clinical schedules depend on the study and setting.
Course frequency
Daily administration appears in many clinical courses; diagnosis and protocol differ.
Infusion speed
Clinical IV studies use slow supervised infusion, not rapid injection.
Missed amount
No universal rule exists across indications or product formats.
Cerebrolysin Route Comparison
| Route | Evidence context | Boundary |
|---|---|---|
| Slow IV infusion | Higher-volume clinical trials | Supervised clinical product |
| Intramuscular | Lower-volume clinical studies and labels | Often limited to about 5 mL per site |
| Subcutaneous | Not established | Not the studied clinical route |
| Powder research vial | Community reported | Not equivalent to clinical liquid |
Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.
Cerebrolysin Half-Life and Dosing Frequency
| Measure | Finding | Evidence limit |
|---|---|---|
| Single half-life | Not established | Multi-component mixture |
| Peptide fractions | Not characterized as one PK curve | Components differ |
| Clinical exposure | Defined by liquid volume and course | Not transferable to powder vials |
| Community frequency | Daily is reported | Not validated |
Cerebrolysin Dosage Chart
| Route | Amount | Frequency | Source | Human validation |
|---|---|---|---|---|
| IV stroke trials | 10–30 mL clinical liquid | Daily for 10–21 days | Human trials | Study design |
| IV TBI trials | 30–50 mL clinical liquid | Daily for 10–21 days | Human trials | Study design |
| IV or IM dementia studies | 5–30 mL clinical liquid | About four weeks | Human trials | Study design |
| Powder-style vial | 20–32 mg | Daily ramp | Community report | No |
Published study values describe those studies. Community-reported values are not validated dosing recommendations.
Cerebrolysin Reconstitution Guide
Concentration: 20 mg/mL
| Entered amount | Volume | U-100 units |
|---|---|---|
| 20 mg | 1 mL | 100 units |
| 40 mg | 2 mL | 200 units |
| 60 mg | 3 mL | 300 units |
- 1.The established clinical product is already a ready-to-use liquid and is not reconstituted.
- 2.Confirm the exact vial label and total quantity.
- 3.Record the measured diluent volume.
- 4.Clean the vial stopper.
- 5.Add liquid slowly along the vial wall.
- 6.Swirl gently; do not shake.
- 7.Inspect for cloudiness, discoloration, or particles.
- 8.Label the calculated concentration and preparation date.
- 9.Use the result only for arithmetic, not as a recommendation.
Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.
How Cerebrolysin Works
Complex mixture
Contains low-molecular-weight peptides and free amino acids rather than one active molecule.
Cerebrolysin Human Trials and FDA Status
Current status · verified September 15, 2026
Prescription product in some countries; not FDA approved
- The 1,071-participant CASTA stroke trial used 30 mL daily for 10 days and did not meet its overall primary endpoint.
- A 2023 Cochrane review found no clear acute-stroke benefit and reported more non-fatal serious adverse events with moderate certainty.
- Dementia reviews describe possible signals but emphasize small, short, heterogeneous trials.
- Traumatic-brain-injury studies report exploratory recovery signals without establishing universal use.
- Healthy-adult nootropic use has little direct evidence.
Who Should Avoid Cerebrolysin?
This is an evidence-gap and precaution list, not an approved prescribing label.
Porcine-product allergy
Anaphylaxis risk
Severe kidney impairment
Label caution in some countries
Epilepsy or seizure disorder
Label caution
Pregnancy or breastfeeding
Safety not established
Unsupervised IV or IM administration
Clinical routes require trained oversight
Assuming vial equivalence
Research powder is not the prescription liquid
Cerebrolysin Side Effects, Risks and Safety
Dizziness, headache, sweating, or nauseaHuman studies
Important limitation: Usually described as mild.
Feeling hot or lightheadedAdministration related
Important limitation: Reported with rapid IV delivery.
Hypersensitivity or anaphylaxisRare serious risk
Important limitation: Porcine-derived mixture.
Non-fatal serious adverse eventsSystematic-review signal
Important limitation: Acute-stroke evidence.
Product contamination or mismatchResearch-vial risk
Important limitation: No equivalence established.
Long-term effectsNot established
Important limitation: Indication-specific evidence.
Cerebrolysin Timeline and Monitoring
10–21 days
Common stroke and brain-injury study-course range.
About four weeks
Duration used in several dementia studies.
30–90 days
Common follow-up window; not a restart schedule.
Cerebrolysin Benefits and Results: What the Evidence Shows
| Claim | Evidence level | What research shows | Important limitation |
|---|---|---|---|
| Acute stroke recovery | Mixed human evidence | Large trials and reviews | No clear overall benefit |
| Dementia cognition | Limited human evidence | Short heterogeneous trials | Not definitive |
| TBI recovery | Exploratory human evidence | Moderate-size programs | Needs confirmation |
| Healthy-adult cognition | Not established | Little direct evidence | Unsupported generalization |
Cerebrolysin Storage and Handling
Clinical sealed liquid
Store below 25°C, protected from light; do not freeze, per product information.
Opened clinical ampoule
Single use; use immediately.
60 mg research vial
No independently verified product-specific stability was identified.
Appearance
Clinical liquid should be clear to slightly yellow; appearance alone cannot verify a research vial.
Cerebrolysin Troubleshooting
Clinical and research-vial amounts conflict
They are different formats and scales; do not combine their math.
A subcutaneous chart appears
Subcutaneous administration is not the established clinical route.
Solution looks abnormal
Do not assume identity or sterility from appearance.
A benefit claim conflicts with a review
Prioritize the relevant systematic review and exact indication.
A scheduled amount is missed
No universal procedure exists across indications.
Cerebrolysin Comparisons
| Compound | Class or mechanism | Evidence | FDA status |
|---|---|---|---|
| Cerebrolysin | Porcine peptide/amino-acid mixture | Mixed randomized clinical evidence | Approved in some countries |
| Cerebroprotein hydrolysate | Related porcine hydrolysate category | Product-specific evidence varies | Not interchangeable |
| Semax | Synthetic ACTH-fragment analogue | Different route and evidence | Not FDA approved |
| Cortagen | Synthetic AEDP tetrapeptide | Primarily preclinical | Not FDA approved |
Cerebrolysin Frequently Asked Questions
What is Cerebrolysin?
A porcine-brain-derived mixture of peptides and amino acids.
Is it one peptide?
No.
Is it FDA approved?
No.
Is it approved elsewhere?
It is prescription-authorized in multiple countries.
What routes were studied?
Primarily slow IV infusion and IM injection.
Does the clinical liquid require reconstitution?
No; it is ready to use.
Is the 60 mg vial equivalent to clinical Cerebrolysin?
Not established.
What is its half-life?
No single half-life describes the mixture.
Did stroke trials prove benefit?
No clear overall benefit was established in the major review.
What does the calculator do?
It performs research-vial concentration arithmetic only.
Sources and Research
Coverage source
1. Cerebrolysin protocol coverage source
Separates clinical liquid trial context from community research-vial claims.
Open direct sourceSystematic review
2. Cerebrolysin for acute ischemic stroke
2023 systematic review of randomized stroke evidence and safety.
Open direct sourceTrial registry
3. CASTA study record
Large randomized acute-stroke trial using 30 mL daily for 10 days.
Open direct sourceMissing information flagged for review
- Equivalence of 60 mg powder to clinical liquid: Not established
- Single-compound pharmacokinetics: Not established
- Validated subcutaneous route: Not established
- Community powder-vial regimen: Not established
- Universal repeat-course criteria: Not established
- U.S. approval: Not established
- Healthy-adult efficacy: Not established